Quality of Life
At EpicentRx™ we’re focused on development of novel therapies designed to target cancer and chronic disease.
Our pipeline includes treatments designed to improve efficacy and tolerability of current approved therapies.
Tony Reid, M.D. Ph.D.
EpicentRx Chief Executive Officer
30-year practicing GI oncologist
The Phase 3 investigational product, RRx-001 is a first-in-class molecule sourced from a portfolio of EpicentRx owned aerospace-derived compounds that targets cancer and chronic inflammatory diseases under the company’s CyNRGY Platform banner.
In addition, research is under way using the eLoop device for enhanced delivery of other standard of care treatments.